Advanced

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia

Kaderi, Mohd Arifin; Mansouri, Mahmoud; Zainuddin, Norafiza; Cahill, Nicola; Gunnarsson, Rebeqa LU ; Jansson, Mattias; Kimby, Eva; Aleskog, Anna; Lundin, Jeanette and Glimelius, Bengt, et al. (2010) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 34(3). p.335-339
Abstract
The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the... (More)
The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. (C) 2009 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Genomic aberrations, Prognostic markers, status, IGHV mutational, Binet stage, MDM2 SNP309, Chronic lymphocytic leukemia
in
Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
volume
34
issue
3
pages
335 - 339
publisher
Elsevier
external identifiers
  • wos:000274529600013
  • scopus:77649181649
ISSN
1873-5835
DOI
10.1016/j.leukres.2009.06.006
language
English
LU publication?
yes
id
06e35f4d-139f-4264-8827-7e9996460d7c (old id 1568854)
date added to LUP
2010-03-17 13:14:46
date last changed
2018-05-29 09:50:52
@article{06e35f4d-139f-4264-8827-7e9996460d7c,
  abstract     = {The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. (C) 2009 Elsevier Ltd. All rights reserved.},
  author       = {Kaderi, Mohd Arifin and Mansouri, Mahmoud and Zainuddin, Norafiza and Cahill, Nicola and Gunnarsson, Rebeqa and Jansson, Mattias and Kimby, Eva and Aleskog, Anna and Lundin, Jeanette and Glimelius, Bengt and Melbye, Mads and Juliusson, Gunnar and Jurlander, Jesper and Rosenquist, Richard},
  issn         = {1873-5835},
  keyword      = {Genomic aberrations,Prognostic markers,status,IGHV mutational,Binet stage,MDM2 SNP309,Chronic lymphocytic leukemia},
  language     = {eng},
  number       = {3},
  pages        = {335--339},
  publisher    = {Elsevier},
  series       = {Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis},
  title        = {Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia},
  url          = {http://dx.doi.org/10.1016/j.leukres.2009.06.006},
  volume       = {34},
  year         = {2010},
}